All News
Find all your AS/Spondyloarthritis coverage from #EULAR2021 in one spot.
https://t.co/owm8LQzHXr https://t.co/5YmDFOvolF
Links:
Dr. John Cush RheumNow ( View Tweet)
Video: RA and Cancer: Myth or Reality? Dr. Jonathan Kay ( @RheumKay )
Dr. Kay reviewed highlights from the "Oncorheumatology: the crossroads of cancer and musculoskeletal diseases" scientific session including abstract OP0187, presented at #EULAR2021.
https://t.co/KaLEZ67L5S https://t.co/6MHXyffO2W
Links:
Dr. John Cush RheumNow ( View Tweet)
Video: The Future of Treatment of RA-ILD: Dr. David Liew ( @drdavidliew )
Dr. David Liew reviews abstract OP0124 presented at #EULAR2021
https://t.co/0dqBPRiwjA https://t.co/XR7cQhPVRw
Links:
Dr. John Cush RheumNow ( View Tweet)
Video: IFN Scores Predict Resistance to Skin Disease During RTX Therapy in Lupus
Dr. Yuz Yusof speaks with Dr. Lucy Carter about abstract OP0134, presented at the virtual #EULAR2021 meeting.
https://t.co/pqr8uRBiRG https://t.co/lhvuYIfI34
Links:
Dr. John Cush RheumNow ( View Tweet)
What's your #EULAR2021 IQ? Answer correctly and climb the leaderboard.
https://t.co/MsI3IFFdqn https://t.co/zJ1an40Yyj
Links:
Dr. John Cush RheumNow ( View Tweet)
Video: Prevalence of Long Term HCQ in Retinal Toxicity: Dr. Kathryn Dao (@KDAO2011 )
Dr. Kathryn Dao reviews abstract OP0133, "The Prevalence and Risk Factors of Retinal Toxicity Associated with Long-Term Hydroxychloroquine Use", presented at #EULAR2021.
https://t.co/tZyXQhZgLG https://t.co/x6AfItFWEU
Links:
Dr. John Cush RheumNow ( View Tweet)
Tune in to our latest podcast on #EULAR2021 and EULAR IQ.
https://t.co/yjId7QNRRR https://t.co/F46FLEilRY
Links:
Dr. John Cush RheumNow ( View Tweet)
#EULAR2021 IL-23 & IL-12/23 coverage in one spot on RheumNow.
https://t.co/sut3zubcow https://t.co/f7XDuRyLB9
Links:
Dr. John Cush RheumNow ( View Tweet)
RA after 70: Too Old for bioDMARDs? by Dr. Aurelie Najm #EULAR2021
In RA, the two most common peaks of incidence are 30s and 50s; however a significant % of patients in 70s present with active RA -of early or later onset- and require adapted treatment.
https://t.co/w6rxT0FmlP https://t.co/fnvSQcu0Fl
Links:
Dr. John Cush RheumNow ( View Tweet)
Video: Difficult to Treat RA: Look out for Comorbidities: Dr. Aurelie Najm #EULAR2021
https://t.co/71Kx0HmmDm https://t.co/iu2p2EXNof
Links:
Dr. John Cush RheumNow ( View Tweet)
@IainBMcInnes1 @NEJM @JWatch @NEJMres360 #rheumatology #rheumtwitter #MedTwitter #VisualAbstract #WorldASDay #spondyloarthritis #psoriasis #psoriaticarhtritis #MedEd #dermatology #JAKi #EBM
https://t.co/dGRi83Wt9x https://t.co/22WacHQZpT
EnvisionRheumat ERheumat ( View Tweet)
OP0140 at #EULAR2021:
➡️Obs, prospect Nordic study characterized axSpA pts w/ high BASDAI + ASDAS & multiple bDMARD use (indicating difficult to tx dz)
➡️1 in 10 received at least 3 bDMARDs
*⃣Multiple switchers were more often F, had higher b/l dz activity, & psoriasis
@Rheumnow https://t.co/syq0szVWKe
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
⭐️TORTUGA = PII trial that showed filgotinib (Jak1-i) signif improv SPARCC MRI scores (BM edema) in the spine + SIJ vs PBO in pts w/ active AS
⭐️OP0141 = post-hoc analysis that showed stat signif ⬇️ of CANDEN MRI scores (new bone format) w/ filgot at wk12
#EULAR2021 @Rheumnow https://t.co/RIpYIMcx1Q
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
➡️Netakimab = IL17Ai approved for AS, PsA, & Pso in Russia & Belarus
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Clive Kelly presents data from INBUILD on nintedanib in progressive fibrosing RA-ILD over 52 weeks FVC decline -82.6 (41.3) mL in nintedanib vs -199.3 (36.2) mL in placebo (p=0.037) @RheumNow #EULAR2021 Abstr#OP0124 https://t.co/MZwzNoq6LC
Richard Conway RichardPAConway ( View Tweet)
⭐️JUNIPERA: RCT of SEC in active ERA & JPsA (2-18yo, most on MTX)
-Tx . (TP)1: SEC 75/100 mg till wk 12
-TP2: cont SEC or switch to PBO till wk 104
⭐️SEC efficacious on JIA ACR30/70
⭐️74% w/ resolution of enthes
⭐️Median T2flare in PBO in TP2 = 453d
LB0004 #EULAR2021 @Rheumnow https://t.co/JsG2pXz9r6
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
What to tell pts about diet?
*⃣Nutrition plays a role in inflammation in RMD & co-morbidities. What you eat matters!
*⃣ LImit salt, replace w/ herbs
*⃣ Consume low glycemic index foods.
Soda ⬆️risk of RA in women
*⃣⬆️omega-3 ⬇️omega-6 (dairy, eggs)
#EULAR2021 @Rheumnow
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
#EULAR2021 POS0236
Comparison of work productivity b/w CBP w & w/o AxSpA - 2 years from SPACE cohort
⭐️AxSpA showed significant ⬇️ in work productivity loss (WPL) compared to CBP wo AxSpA
Can use to counsel AxSpA patients that we have effective Rx for return to work
@RheumNow
Eric Dein ejdein1 ( View Tweet)
#EULAR2021 POS0237: Gut dysbiosis linked to worse disease status in axSpA.
⭐️Dysbiosis in 33% of AxSpA vs 17% of controls wo rheumatic disease
⭐️Gut dysbiosis associated with worsening disease activity
@RheumNow https://t.co/rRl4Zbs7xc
Eric Dein ejdein1 ( View Tweet)
BUT.....the SEC results were significant if you only looked at those with moderate to severe rotator cuff tendinopathy? Curious study, I think worthy of a well designed prospective trial. https://t.co/kqGink3sjU
Dr. John Cush RheumNow ( View Tweet)
